Article
[A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 20 May 2019
Gao Y H, Li G M, Jin Q L, Zhao Y R, Jia Z S, Mao X R, Yang Y F, Shang J, Wang G C, Xie W, Wu S M, Zhang M X, Hou J L, Li D L, Nan Y M, Guan Y J, Zhu C X, Yuan Y Z, Wei L
Abstract excerpt
Objective: To evaluate the efficacy and safety of sofosbuvir (Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.) combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection. Methods: Treatment-naïve or treatment experienced genotype 2 chronic hepatitis C patients from sixteen research centers of China were screened. All subjects received once-daily dose of sofosbuvir (400 mg) combined...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.